鼓膜穿孔（TMP）是耳鼻咽喉科临床常见病及多发病，是主要的致聋性疾病。慢性TMP的治疗是现今临床尚需解决的难题，传统手术修补方式费用高昂、技巧复杂、创伤较大，并且至今仍缺乏一种理想的鼓膜移植材料。本研究旨在采用一种新型I/III型胶原蛋白支架与种子细胞复合构建成为组织工程鼓膜，并通过体外和动物实验研究其对慢性TMP的再生修复效果，包括穿孔修复和听力康复，探讨一种更为安全、微创、高效、经济、简便并易于向临床推广的慢性TMP治疗方法。如果本项目能够证实该治疗新策略具有促进鼓膜再生修复及听力重建的疗效，那么将为利用组织工程学方法治疗慢性TMP的深入探索研究奠定基础，并能为临床新诊疗技术的开展提供科学依据。

Tympanic membrane perforations (TMP) are common in outpatient settings, which lead to significant hearing loss and may promote infection of the middle ear. Currently, surgical procedures (e.g. myringoplasty) are still routinely performed although with limitations such as high cost, complex skills and donor site morbidity. Moreover, all graft materials have associated limitations. The aim of this study is to develop a novel tissue-engineered tympanic membrane with collagen type I/III scaffolds and seed cells, and to evaluate its efficacy, both from a healing and hearing perspective for the repair of chronic TMP in a rat model. We hypothesized that this type I/III collagen-cell complex would promote tympanic membrane regeneration, enhancing perforation wound healing and hearing restoration. Therefore, this study will be beneficial to further carry out tissue engineering technology for the repair of TMP in clinical settings.